Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

From Subsea to Life On Land

Gasket Technology Follows DarwinismMetal-to-metal sealing technology is a technique that had previously been reserved for subsea oil and gas applications where meeting the most extreme operational criteria has always been required. Such criteria demand that any equipment, tools, and sealing technology must withstand extreme crushing depths where environmental pressures and temperatures will easily destroy any object that falls victim to their reach. However, now this revolutionary technology has made landfall and is changing the landscape of onshore operations. It has quickly begun

#19-1023 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Decisions from Bambuser’s Extra General Meeting August 23, 2019

The shareholders of Bambuser AB (publ) have today, on Friday, August 23, 2019, had an Extraordinary General Meeting, where decisions were taken to amend the Articles of Association, directed new issues of shares, non-cash issue, share issue authorization and election of a new Board member.The Meeting resolved, in accordance with the Board's proposal, to change the limits of the Articles of Association so that the share capital should amount to a minimum of SEK 1,875,000 and a maximum of SEK 7,500,000, and that the number of shares should be at least 37,500,000 and a maximum of 150,000,000.

The exercise period of TO4 starts August 25.

August 25 – September 8 2019 is exercise period of Brighter TO4 during which holders of the warrants can subscribe for shares. One (1) TO4 can be exchanged for one (1) share during the period, at a price of SEK 6.01. Holders of warrants who have their warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the warrants and subscribe for the corresponding shares. Exercise of the warrants and subscription of shares for other holders of warrants takes place through simultaneous payment and submittal of the

Net sales continued to grow in the second quarter, operating profit still suppressed by project mix

DELETE GROUP OYJ, STOCK EXCHANGE RELEASE 23 August 2019 at 16:35 EEST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. DELETE GROUP OYJ Interim Financial Statements January–June 2019 (IFRS, IAS 34, unaudited)  NET SALES CONTINUED TO GROW IN THE SECOND QUARTER, OPERATING PROFIT STILL SUPPRESSED BY PROJECT MIX   HIGHLIGHTS OF APRIL–JUNE 2019  · Net sales increased by 8% to EUR 56.6 (Q2 2018: 52.4) million  · EBITDA decreased by EUR -

Immunovia Interim Report, January-June 2019

“The second quarter 2019 was particularly successful as we hit a key milestone and reached several key objectives as the optimization work was completed. We are continuing to ramp up towards commercializing IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer. At the beginning of June, we announced excellent results from IMMray™ PanCan-d’s optimization work. This study, performed in collaboration with Prof. Stephen Pereira of the University College of London, is the first ever to achieve such results where pancreatic cancer (PDAC, pancreatic ductal

Hydro-Québec drives pension plan growth, with SimCorp’s front-to-back, multi-asset investment management solution

PRESS RELEASE SimCorp , a leading provider of investment management solutions  and services to the global financial services industry, announces that it has signed a license agreement with Hydro-Québec’s pension plan, for the use of SimCorp’s front-to-back investment management system, SimCorp Dimension. The license will see SimCorp Dimension form the core investment platform at Hydro-Québec’s pension plan, supporting its CAD $24.7 billion retirement plan and enabling growth, through the coverage of new asset classes and instruments. Hydro-

MRSI to present at 18th ICCSZ OC Market and Technology Seminar and offer die bonder demonstrations at CIOE

MRSI Systems and CYCAD Century Science and Technology will partner together at the 21st China International Optoelectronic Exposition (CIOE). Product demos will be offered at Cycad’s booth #1C86. The show will be held at the Shenzhen Convention and Exhibition Center from September 4-7, 2019.MRSI Systems will also attend the 18th ICCSZ OC Market and Technology Seminar. This event is organized by Infostone Communication Consultant (ICCSZ) in Shenzhen, China, from September 2-3, 2019. Dr. Yi Qian, Vice President of Marketing, MRSI Systems, will be presenting “Progress in Assembly Automations:

Metsä Board Corporation: Managers’ transactions

Metsä Board Corporation Managers’ transactions 23 August 2019 at 4 pm EESTMetsäliitto Cooperative, which is a closely associated party to Metsä Board’s chairman and two members of the Board, has acquired on 20 August 2019 and 21 August 2019 Metsä Board Corporation’s B shares. More specific information on the transactions can be found in the tables below: +-----------------------------+-------------------------------------+|Closely associated legal |Metsäliitto Cooperative ||party subject to the | ||notification:

Purchase of subscription rights and subscription for shares in the subsequent offering by primary insiders

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the subsequent offering (the “Subsequent Offering”) in Norwegian Energy Company ASA (the “Company”) as previously announced, latest on 12 August 2019. Marianne Lie, board member of the Company, has today through Fajoma Consulting AS, a

Nordic Nanovector ASA: Mandatory notification of trade - primary insider - correction

With reference to the previous notification of trade, the correct number of shares purchased today, 23 August 2019, by Malene Brondberg is not 1,722 shares, but 3,900 shares in Nordic Nanovector ASA (the "Company") at an average share price of NOK 25.38 per share. Following this transaction, Malene Brondberg owns 9,455 shares in the Company and holds 40,000 PSUs. This information is subject to duty of disclosure pursuant to Section 4-2 and Section 5-2 of the Norwegian Securities Trading Act.

Inhalation Sciences receives new order worth 1.8 MSEK

(Stockholm August 23 2019) Inhalation Sciences Sweden AB has received an order for a new PreciseInhale system from an existing customer with global lab facilities. The new order includes a range of exposure modules and PreciseInhale’s new customized nebulizer feature.CEO Lena Heffler: “I’m pleased to see this trend of existing customers returning to purchase a second instrument from ISAB. It speaks volumes about the quality of data, range of capabilities and important competitive edge PreciseInhale gives them”. ISAB’s PreciseInhale aerosol generator generates accurate in vivo and ex vivo

Crunchfish: Blippit on track for Q4 launch (Västra Hamnen)

Västra Hamnen Corporate Finance has released a research update on Crunchfish AB following its report for Q2 2019. The company shows progression in line with our economic scenario, which confirms our estimated fair value interval for the share.· App terminal getting ready for production · Gesture Control becoming more powerful and user friendly · We maintain our fair value per share estimates of SEK 32.60 – 51.80 In its report for Q2 2019, Crunchfish confirms that their business expansion is progressing according to plan. The report contains few surprises and the company’s

Salmones Camanchaca commits to become Carbon Neutral by 2025

•        Will implement a strategic plan that will prioritize reductions in the use of fossil fuels, electricity and refrigerants, which are the main sources of greenhouse gas (GHG) emissions of the Company, and will promote forest stewardship projects. •        Announcement was made in Oslo, Norway, in the context of its Capital Markets Day, the first to be carried out by a Chilean capital company in that country. Oslo, Norway, August 23, 2019.- Always seeking to reduce its environmental footprint and promote the sustainable development of aquaculture, Salmones Camanchaca reported

Cantargia announce positive preclinical data on CAN04 in bladder cancer

Cantargia AB today announce new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The molecular target for CAN04, IL1RAP, has been detected on the cancer cells in approximately 80 % of patients with bladder cancer. Furthermore, a pronounced and statistically significant single agent activity was documented in an in vivo model of the disease. Given current treatment strategies of bladder cancer, there are several future opportunities for CAN04 in this disease.Cantargia’s antibody CAN04 binds IL1RAP with high affinity and

Interim report January – June 2019

APRIL – JUNE 2019 · Revenue amounted to MSEK 1,667 (1,616), an increase of 3%. Organically, a decline of 4.7%. · Operating profit was MSEK -137 (11), which included a write-down of intangible assets amounting to MSEK 124 (0) regarding operations in Finland and items affecting comparability of MSEK -25 (-25). · Adjusted EBITA was MSEK 47 (69) and the corres-ponding margin was 2.8% (4.3). · Net loss for the period was MSEK -142 (-11) · Earnings per share before and after dilution was SEK -4.35 (-0.65). · The period’s cash flow was MSEK 1 (-32). · Taxi 4x27 in Denmark

Cyxone strengthens team ahead of continued development of T20K and Rabeximod

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company is expanding its team with Malin Berthold as project manager for the next step in the development of Cyxone's clinical drug portfolio. Malin will primarily lead and coordinate the preclinical and clinical development programs in the company. She will be the company's primary contact with external key partners such as CROs, toxicology laboratories, pharmaceutical manufacturers, formulation experts, analysis laboratories and communication experts. Further responsibility is to regularly report the

Interim report January – June 2019

Profitability and acquisitions ahead of planApril – June January – June 20192019 ·  Net sales increased by 21.9 percent to SEK 2,624 (2,153) ·  Net million. Organic growth was 2.0 (8.5) percent.sales ·  Adjusted EBITA increased to SEK 215 (180) million, whichincreased by corresponds to an adjusted EBITA margin of 8.2 (8.4) percent.19.8 percent ·  Operating cash flow for the period was SEK 282 (231)to SEK 1,406 million.(1,174) ·  Eight acquisitions were made during the first half of themillion. year, which, on an annual basis

There are no items matching the current filter
There are no more items matching the current filter
Back to top